Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting
WALTHAM, Mass. April 27, 2021
Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced an oral presentation and three digital posters have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, taking place virtually May 11-14, 2021.
The presentations will showcase Affinia Therapeutics’ vectors, which have enhanced tropism for the central nervous system, safety such as liver de-targeting, and improved manufacturing yields. The data provides insight into the company’s viral vector library of novel AAVs, its AAV ancestral sequence reconstruction platform, and the potential of this platform to broaden the reach of gene therapies. Details for the oral presentation and posters are as follows:
Oral Presentation
Title: AAVX Resin Binding Site Identification Via Library Screening Analysis on Novel AAV Vectors
Education Session Title: Downstream Process of Vector Manufacturing
Date and Time: Thursday, May 13, 2021, 6:30-6:45 p.m. ET
Room: 9
Abstract Number: 170
Digital Posters
Title: CSF Delivery of Anc80L65 in Nonhuman Primates Results in More Widespread Gene Transfer Throughout the Central Nervous System Compared to AAV9
Date and Time: Tuesday, May 11, 2021, 8:00-10:00 a.m. ET
Poster Session Title: AAV Vectors – Preclinical and Proof-of-Concept Studies
Abstract Number: 362
Title: Network Analysis of Complex Novel AAV Vector Library Datasets for De-risking Gene Therapy Candidate Selection
Date and Time: Tuesday, May 11, 2021, 8:00-10:00 a.m. ET
Poster Session Title: AAV Vectors – Virology and Vectorology
Abstract Number: 285
Title: AAVmod2, An AAV Capsid Engineered to Independently Detarget the Liver and Enhance Gene Delivery to Skeletal Muscle
Date and Time: Tuesday, May 11, 2021, 8:00-10:00 a.m. ET
Poster Session Title: AAV Vectors – Virology and Vectorology
Abstract Number: 286
Founded in 2019, Affinia Therapeutics’ science originates from work done by Luk Vandenberghe, Ph.D., associate professor at Massachusetts Eye and Ear and Harvard Medical School and a co-inventor of AAV9. The Company recently expanded its state-of-the-art discovery laboratories in Waltham, Mass., to add process science, analytical development, and manufacturing pilot plant capabilities as it advances its programs into the clinic.
About Affinia Therapeutics
Affinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics’ proprietary Affinia Rationally designed Therapeutics (ART) platform is intended to synergistically improve the efficacy, safety, and manufacturability of adeno-associated virus (AAV)-based gene therapies through the development of next-generation capsids, promoters, and manufacturing approaches. For more information, visit https://www.affiniatx.com.
Contact Information
Investors: investors@affiniatx.com
Media: Kathy Vincent, media@affiniatx.com